Source published October 15, 2026: Salience TMS Neuro Solutions vendor announcement distributed through PR Newswire. The peer-reviewed study was first published online August 19, 2026, and is not presented here as new October research.
A different treatment timeline The announcement highlights ONE-BD, a retrospective case series exploring whether an entire course of intermittent theta-burst stimulation could be delivered in one day for adults with bipolar I depression. All 30 participants received 20 three-minute sessions, spaced about 20 minutes apart, with a single 125 mg dose of D-cycloserine before treatment.
The practical idea is important. Conventional TMS schedules can require repeated clinic visits over several weeks. Compressing sessions into one carefully monitored day could reduce that burden if controlled research eventually confirms safety, effectiveness and appropriate patient selection.
What was reported All 30 participants completed the treatment day. The vendor announcement reports no serious adverse events and no switch to mania or hypomania. Depression scores improved over the following weeks. At six weeks, 73.3 percent met the study's clinician-rated response criterion and 43.3 percent met its remission criterion.
Why caution still matters This was a small retrospective case series without a sham or active comparison group. It combined accelerated iTBS with D-cycloserine, so the report cannot isolate stimulation effects or rule out expectancy, concurrent care, natural change or other influences. Thirty participants are also too few to establish uncommon risks, especially in bipolar disorder. The authors and company announcement describe the findings as preliminary and call for randomized controlled studies.
Commercial and funding context The announcement comes from Salience, whose researchers contributed to the study, and identifies Ampa Health as a collaborating neurotechnology company. Crossref lists Ontario Brain Institute, Canadian Institutes of Health Research and Brain Canada Foundation funding for the publication. These relationships do not invalidate the results, but they belong in a transparent reading of the report.
Why it matters ONE-BD puts a concrete access question on the research agenda: can a highly compressed schedule retain benefit and acceptable safety while reducing repeated travel? The case series is an encouraging first signal, not evidence that single-day TMS should replace established care or an FDA-cleared bipolar-depression indication.
Disclosure This is coverage of a vendor announcement and its linked peer-reviewed case series, not a clinical endorsement. Prepared with AI assistance; announcement and Crossref publication record checked October 19, 2026.